Absci Corporation announced on December 11, 2025 that its AI‑designed antibody ABS‑201 produced new human ex‑vivo data demonstrating the ability to stimulate hair growth and regenerate the stem‑cell niche in human scalp skin. The data, generated from organ‑cultured, full‑thickness scalp samples from male donors, showed that ABS‑201 significantly inhibited prolactin‑receptor signaling, prolonged the anagen (growth) phase, and increased keratin production and key growth factors. The findings were presented at a virtual Key Opinion Leader seminar held on Thursday, December 11, 2025, and are the first evidence that the antibody can reverse follicle miniaturization and convert vellus hairs into terminal hairs.
The preclinical results support Absci’s strategy to target prolactin signaling as a novel mechanism for treating androgenetic alopecia. By extending the anagen phase and preserving stem‑cell populations, ABS‑201 could offer a more durable and effective therapy than current options such as minoxidil and finasteride. The data also provide a critical step toward the planned Phase 1/2a clinical trial, which is expected to begin in early 2026.
Absci’s integrated drug‑creation platform, which couples generative AI with high‑throughput wet‑lab validation, enabled the rapid design and testing of ABS‑201. The company’s leadership highlighted that the new ex‑vivo evidence strengthens the scientific rationale for the program and may accelerate regulatory discussions. The announcement is a key milestone for Absci’s pipeline and signals progress toward a first‑in‑class therapy for a market of over 80 million Americans affected by androgenetic alopecia.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.